reports
PAVmed Inc: 1 director
A director at PAVmed Inc maiden bought 250,000 shares at 0.644USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Dave Nicoski
- Ross LaDuke
W9N WNS (HOLDINGS) LIMITED SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
PTCT PTC THERAPEUTICS INC.
MYGN MYRIAD GENETICS INC.
LMAT LEMAITRE VASCULAR INC.
ITCI INTRA-CELLULAR THERAPIES INC.
ISRG INTUITIVE SURGICAL INC.
INSM INSMED INCORPORATED
GBT GLOBAL BLOOD THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
DVAX DYNAVAX TECHNOLOGIES CORPORATION
CYTK CYTOKINETICS INCORPORATED
EVRI EVERI HOLDINGS INC.
PAVM PAVMED INC
DFIN DONNELLEY FINANCIAL SOLUTIONS INC.
TTEC TTEC HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
KRYS KRYSTAL BIOTECH INC
EVOP EVO PAYMENTS
YMAB Y-MABS THERAPEUTICS
ALLO ALLOGENE THERAPEUTICS
GOSS GOSSAMER BIO
APYX APYX MEDICAL
SGEN SEAGEN INC.
BEAM BEAM THERAPEUTICS
TVTX TRAVERE THERAPEUTICS INC
PAYA PAYA HOLDINGS INC (A)
KRTX KARUNA THERAPEUTICS INC
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named T...
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, today announced that PAVmed and Lucid Chairman & Chief Executive Officer was selected as one of the Top 50 Healthcare Technology CEOs of 2022 by . This press release features multimedia. View the full release here: “I would like to thank The Healthcare Technology Report for this honor,” said Dr. Aklog. “I am so fortunate to work with a rapidly gro...
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2...
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented preliminary financial results for the three months ended March 31, 2022. Conference Call and Webcast A conference call and webcast for today’s business update and first quarter 2022 financial results will take place at ...
PAVmed Announces Procedural Update on its Settlement of a Previously D...
PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit. As previously disclosed, on January 28, 2021, the Company entered into a term sheet agreement for the settlement of a previously disclosed putative class action lawsuit commenced in November 2020, captioned Spritzer v. PAVmed...
PAVmed to Hold a Business Update Conference Call on May 12, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, at 4:30 PM EDT. During the call, , Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, , PAVmed’s Chief Financial Officer, will discuss the Company’s first quarter 2022 financial results. To access the conference call, U.S.-based listeners s...
PAVmed Announces Successful First-in-Human Implantations of its PortIO...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients. All patients have also undergone successful infusion of fluids consistent with the study protocol and the device’s intended use. No complications hav...
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisor...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company today announced that its majority-owned digital health subsidiary Veris Health (“Veris”) has launched a world-class technology advisory board consisting of Silicon Valley luminaries with broad expertise in software development, hardware engineering, data and analytics, machine learning, and consumer engagement. Silicon Valley pioneer Rich Page, an early Apple alumnus who co-founded NeXT Computer with Steve Jobs, will serve as chair. The advisory board held its ina...
PAVmed to Hold a Business Update Conference Call on March 29, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on Tuesday, March 29, 2022, at 4:30 PM EDT. During the call, , Chairman, and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, , PAVmed’s Chief Financial Officer, will discuss the companies’ fourth quarter 2021 financial results. To access the conference call, U.S.-based liste...
PAVmed Appoints Shaun O’Neil as Chief Operating Officer
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of Shaun O’Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O’Neil has served as PAVmed’s Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 20...
Evernorth Executive and Healthcare Services Industry Leader Joan Harve...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. Ms. Harvey will serve as a member of the Company’s Audit and Compensation Committees. This press release features multimedia. View the full release here: PAVmed appoints Joan Harvey to its Board...
PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations ...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company, today announced they have launched a new, full-time investor relations team to serve both companies. This press release features multimedia. View the full release here: Adrian K. Miller has been appointed Vice President, Investor Relations, with broad strategic responsibilities across all aspects of investor communications,...
PAVmed and Lucid Provide Business Update and Preliminary Third Quarter...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company today provided a joint business update for the companies and discussed preliminary financial results for the six and nine months ended September 30, 2021. This press release features multimedia. View the full release here: “The third quarter and recent weeks have proved to be an exciting time for our co...
Veris Health Showcased in PAVmed Digital Health Virtual Investor Event
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, hosted a virtual investor event with several hundred participants on October 26, 2021. The event, Veris Heath: Bringing Digital Health to Cancer Care, focused on PAVmed’s digital health subsidiary Veris Health (“Veris”). The and are now available for viewing. The panelists provided a comprehensive overview of Veris’ disruptive technology, vision, business model, and strategy. They discussed how PAVmed’s entry into th...
PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as C...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its digital health subsidiary Veris Health (“Veris”) today announced the appointment of Silicon Valley technology executive Sunny Webb as Veris’ Chief Technology Officer and PAVmed’s VP, Data & Analytics. This press release features multimedia. View the full release here: Sunny Webb appointed as Chief Technology Officer for PAVmed Digital Health Subsidiary Veris Health (Photo: Business Wire) Ms. Webb will be joining other Veris leade...
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection dev...
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection device which has been used in pre-commercial clinical research of esophageal p...
PAVmed to Host Digital Health Virtual Investor Event
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that on October 26, 2021, from 1 to 3 PM EDT, it will host a virtual investor event focused on its digital health subsidiary Veris Health (“Veris”) entitled Veris Heath: Bringing Digital Health to Cancer Care. Attendees may register for the event . The event will provide a comprehensive overview of Veris’ disruptive technology, vision, business model and strategy. Participants will learn how Veris seeks ...
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its majority-owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), announced yesterday that Lucid has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Lucid Diagnostics intends to list its common stock o...
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Pro...
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Veris Health Inc. (“Veris”) has been accepted into Microsoft for Startups, a global program from Microsoft dedicated to accelerating the trajectory of startups. The Company also announced that Veris has entered into a definitive services agreement with leading full-service Silicon Valley-based full-stack software development firm Loka Inc. (“Loka”) to build its remote digital hea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.